Catalyst Pharma Reports Strong Q3 2025 Financial Results

An update from Catalyst Pharma ( (CPRX) ) is now available.

Catalyst Pharmaceuticals reported strong financial results for the third quarter of 2025, with total revenues of $148.4 million, driven by the growth of FIRDAPSE® and AGAMREE®. The company raised its full-year revenue guidance to between $565 million and $585 million, reflecting better-than-expected performance. Despite a decline in FYCOMPA® revenue due to generic competition, the company remains confident in its growth trajectory, as evidenced by a new $200 million share repurchase program. Additionally, Catalyst settled a patent litigation case with Lupin Ltd., allowing the marketing of generic FIRDAPSE beginning in February 2035.

The most recent analyst rating on (CPRX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Spark’s Take on CPRX Stock

According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.

Catalyst Pharma’s strong financial performance and positive earnings call are the primary drivers of the high stock score. The company’s robust revenue growth, strategic initiatives, and solid balance sheet position it well for future growth. Technical analysis and valuation provide additional support, though cash flow volatility and competition challenges are minor concerns.

To see Spark’s full report on CPRX stock, click here.

More about Catalyst Pharma

Catalyst Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing innovative therapies for people with rare diseases. Their primary products include FIRDAPSE®, AGAMREE®, and FYCOMPA®, with a market focus on conditions such as Lambert-Eaton myasthenic syndrome and Duchenne muscular dystrophy.

Average Trading Volume: 1,506,268

Technical Sentiment Signal: Buy

Current Market Cap: $2.61B

For detailed information about CPRX stock, go to TipRanks’ Stock Analysis page.